Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which may develop from different endocrine glands (such as the pituitary, the parathyroid or the neuroendocrine adrenal glands), endocrine islets (within the thyroid or pancreas) as well as from endocrine cells dispersed be...

Полное описание

Библиографические подробности
Главные авторы:	Grozinsky-Glasberg, S, Shimon, I, Korbonits, M, Grossman, AB
Формат:	Journal article
Язык:	English
Опубликовано:	2008

Схожие документы

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
по: Grozinsky-Glasberg, S, и др.
Опубликовано: (2008)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
по: Kaltsas, G, и др.
Опубликовано: (2005)

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
по: King, C, и др.
Опубликовано: (1993)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
по: Gupta, P, и др.
Опубликовано: (2014)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
по: Ur, E, и др.
Опубликовано: (1993)

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
по: Su-Chen Li, и др.
Опубликовано: (2012-01-01)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
по: Baldelli Roberto, и др.
Опубликовано: (2010-03-01)

Somatostatin analogues therapy in gastroenteropancreatic neuroendocrine tumours: current aspects and new perspectives
по: Roberto eBaldelli
Опубликовано: (2014-02-01)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
по: Sen Gupta, P, и др.
Опубликовано: (2014)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
по: Rihards Saksis, и др.
Опубликовано: (2023-02-01)

Efficacy of somatostatine analogues in survival and quality of life of a frail patient with poorly differentiated biliary neuroendocrine tumour
по: Marco Alì, и др.
Опубликовано: (2015-10-01)

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
по: Hubina, E, и др.
Опубликовано: (2006)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE
по: Ralf S. Eschbach, и др.
Опубликовано: (2023-01-01)

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.
по: Chahal, H, и др.
Опубликовано: (2011)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.
по: Cakir, M, и др.
Опубликовано: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
по: Cakir, M, и др.
Опубликовано: (2010)

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours
по: Peter Wiesli, и др.
Опубликовано: (2019-10-01)

Evaluation of the Association between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
по: Den Gupta, P, и др.
Опубликовано: (2011)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
по: Grozinsky-Glasberg, S, и др.
Опубликовано: (2011)

AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.
по: Chahal, H, и др.
Опубликовано: (2010)

Update on neuroendocrine tumours
по: Grossman, AB
Опубликовано: (2012)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
по: Sebastian Krug, и др.
Опубликовано: (2019-01-01)

Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours
по: Halfdan Sorbye, и др.
Опубликовано: (2020-06-01)

Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
по: Inbal Uri, и др.
Опубликовано: (2018-07-01)

Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms.
по: Kaltsas, G, и др.
Опубликовано: (2014)

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
по: Kaltsas, G, и др.
Опубликовано: (2001)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
по: Fernando Sebastian-Valles, и др.
Опубликовано: (2023-03-01)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
по: Sheila D. Rustgi, и др.
Опубликовано: (2021-05-01)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
по: Joana Lima Ferreira, и др.
Опубликовано: (2021-05-01)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
по: Ström T, и др.
Опубликовано: (2019-10-01)

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues
по: Wenjuan Liu, и др.
Опубликовано: (2017-01-01)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
по: Ur, E, и др.
Опубликовано: (1992)

Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487
по: Carroll, P, и др.
Опубликовано: (2003)

Growth hormone-releasing peptides (GHRP) and their analogues
по: Korbonits, M, и др.
Опубликовано: (1996)

[Growth hormone-releasing peptides (GHRP) and their analogues]
по: Korbonits, M, и др.
Опубликовано: (1996)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
по: Grozinsky-Glasberg, S, и др.
Опубликовано: (2008)

Paraneoplastic syndromes secondary to neuroendocrine tumours.
по: Kaltsas, G, и др.
Опубликовано: (2010)

Antiangiogenic effects of somatostatin analogues.
по: García de la Torre, N, и др.
Опубликовано: (2002)

Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours
по: Pedro Marques, и др.
Опубликовано: (2019-11-01)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
по: Jenkins, P, и др.
Опубликовано: (2000)